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1554Objective: The feasibility of transapical valve-in-valve aortic valve implantation into a failed aortic surgical
bioprosthesis has been confirmed. The purpose of the present study was to investigate the clinical and hemody-
namic outcomes more than 2 years after transapical valve-in-valve aortic valve implantation.
Methods: From April 2007 to May 2010, 8 consecutive patients underwent transapical valve-in-valve aortic
valve implantation of either 23- or 26-mm Edwards-SAPIEN balloon-expandable bioprostheses into failed sur-
gical tissue valves (21- to 25-mm valves). Clinical and echocardiographic follow-up was performed in all pa-
tients. The mean follow-up duration was 27.8  15.7 months (range, 18-55 months).
Results: Transapical valve-in-valve aortic valve implantation was successful in all patients (mean age,
84.1  1.6 years). The predicted operative mortality was 42.1%  15.7% by logistic European System for
Cardiac Operative Risk Evaluation and 14.4%  9.6% using the Society of Thoracic Surgeons risk calculator.
The observed 30-day mortality was 12.5%. No strokes or valve embolization/migrations occurred. The mean
hospital stay was 9.0  9.1 days. The New York Heart Association class decreased from preoperative class
III-IV to postoperative class I in 6 of 7 survivors. The 2-year survival was 87.5%. No late mortality occurred
during the follow-up period. The echocardiographic results at 1 to 4 years of follow-up demonstrated stable valve
position and function in all patients. The transaortic valve pressure gradients after valve-in-valve aortic valve
implantation were greater than 20 mm Hg and less than 15 mm Hg in patients with 21- or 23-mm and
25-mm surgical valves, respectively.
Conclusions: Transapical valve-in-valve aortic valve implantation provides good clinical outcomes and stable
valve function beyond 2 years of follow-up. The best hemodynamic and clinical outcomes can be achieved in the
patients with a surgical valve size of 25 mm or greater. Valve-in-valve aortic valve implantation could become
a viable approach for selected high-risk patients with failed surgical bioprostheses. (J Thorac Cardiovasc Surg
2013;145:1554-62)Redo open-heart aortic valve replacement (AVR) remains
the standard therapy for failed prosthetic valves. Redo iso-
lated AVR carries a low risk of operative mortality and mor-
bidity in most patients. However, bioprosthetic dysfunction
or degeneration is more frequently observed in the elderly
population, because bioprostheses are usually recommen-
ded in older patients. The risk of reoperative mortality
and morbidity increases in elderly patients,1,2 particularly
in those with comorbidities or patent coronary bypass
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The Journal of Thoracic and Cardiovascular Surwith degenerated bioprostheses are likely declined or not
referred for redo AVR because of unacceptable operative
mortality and morbidity. Recently minimally invasive
transcatheter aortic valve implantation (AVI) has been
demonstrated to be an alternative definitive therapy for
patients with severe native aortic stenosis who would be
at unacceptable high risk with conventional AVR.3-11 The
feasibility of transcatheter valve-in-valve implantation
into failed surgical valves has been confirmed. We and
others have reported the 30-day outcomes of transapical
valve-in-valve AVI into failed surgically implanted biopros-
theses.12-14 In the present study, we report the clinical and
echocardiographic outcomes more than 2 years after
transapical valve-in-valve AVI in patients with a mean
follow-up of 27.8  15.7 months, the longest follow-up
for a case series.METHODS
The procedures were approved by the Therapeutic Products Directorate,
Department of Health and Welfare, Ottawa, Ontario, Canada, for compas-
sionate clinical use in patients deemed not to be candidates for open heart
surgery.gery c June 2013
Abbreviations and Acronyms
AVI ¼ aortic valve implantation
AVR ¼ aortic valve replacement
NYHA ¼ New York Heart Association
TEE ¼ transesophageal echocardiography
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All patients with symptomatic failed bioprostheses were assessed inde-
pendently by cardiologists and cardiac surgeons and accepted for the pro-
cedure on the consensus that conventional re-do AVRwas excessively high
risk in terms of anticipated mortality and morbidity. The European System
for Cardiac Operative Risk Evaluation and Society of Thoracic Surgeons
score were not used to determine the fitness for open-heart AVR. All
patients provided written informed consent. From April 2007 to May
2010, 8 patients (2 women) underwent transapical transcatheter valve-in-
valve AVI of either 23- or 26-mm Edwards-SAPIEN balloon-expandable
transcatheter valve into failed surgically implanted bioprostheses. Themin-
imum follow-up period in the present case series was 18 months.
Preoperative Preparation and Assessment
Transthoracic echocardiography and diagnostic cardiac catheterization
were a part of the routine preoperative evaluation. Transesophageal echo-
cardiography (TEE) was performed to evaluate the bioprosthetic leaflet
morphology or paravalvular regurgitation. The internal diameters of the
surgical tissue valves in all patients, except for 1, were obtained from the
information provided by the manufacturers. Important paravalvular leaks,
endocarditis, and surgical valves that were too small were considered
exclusions.
Valve-in-Valve Implantation Technique
The procedure for transapical transcatheter valve-in-valve AVI into
a failed surgical bioprosthesis was quite similar to that for transapical
AVI into a native aortic valve, which has been previously described in
detail.6,15,16 In brief, the procedure was performed with the patient under
general anesthesia in a hybrid operating room. Balloon valvuloplasty was
not performed. Balloon-expandable transcatheter bioprostheses (Edwards
SAPIEN transcatheter heart valve; Edwards Lifesciences, Irvine, Calif)
for failed bioprostheses were used in our patients (Figure 1). Fluoroscopic
and/or TEE imaging were sufficient for valve positioning. Intraoperative
conventional aortography was not performed during valve positioning.
For surgical valves with a radiopaque metal frame, optimal valve position-
ing mainly relied on the visualization of the region of the sewing cuff on
fluoroscopy (Figure 2). For the valve without a radiopaque metal frame
at the base (sewing cuff) of a bioprosthesis, valve positioning was per-
formedwith the assistance of TEE (Figure 3). Final positioning of the trans-
catheter valve was determined with rapid ventricular pacing before the
deployment of a valve. Selection of the Edwards transcatheter valves for
valve-in-valve implantation was determined by the estimated inner diame-
ter of the failed surgical bioprostheses. All valve-in-valve procedures were
performed without support of cardiopulmonary bypass. Postoperatively,
the patients were instructed to take aspirin indefinitely and clopidogrel
for at least 3 months. Warfarin was used if other indications were present,
such as atrial fibrillation.Follow-up and Data Collection
All patients were followed up by cardiac surgeons and clinical fellows.
Follow-up included telephone interviews and office visits. The New York
Heart Association (NYHA) class was assessed by either clinical fellows
or staff surgeons. Follow-up echocardiography was performed either atThe Journal of Thoracic and Carour hospital or others and was read by the staff echocardiologists. The clin-
ical follow-up and echocardiographic data were obtained before discharge,
at 1, 6, and 12 months, and then yearly. The mean follow-up period was
27.8  15.7 months (range, 18-55 months) with a total of 222 months of
follow-up. Data were collected prospectively and presented as
mean  standard deviation. The Valve Academic Research Consortium
definitions were used.17
RESULTS
Patients
Themean patient agewas 84.1 1.6 years. The predicted
perioperative mortality was 42.1%  15.7% using the
logistic European System for Cardiac Operative Risk Eval-
uation and 14.4%  9.6% using the Society of Thoracic
Surgeons risk calculator. Patients had various types of
surgically implanted aortic bioprostheses, including the
Carpentier-Edwards porcine valve (Edwards Lifesciences),
Medtronic Mosaic valve (Medtronic, Minneapolis, Minn),
Sorin Mitroflow pericardial valve (Sorin Group, Milan,
Italy), and Ionescu-Shiley pericardial valve (Shiley Inc,
Irvine, Calif). These surgical valves were implanted
13.6  7.0 years (mean  standard deviation) before the
valve-in-valve procedure. All patients presented with sig-
nificant aortic stenosis, and 3 patients had concomitant se-
vere aortic regurgitation. The baseline characteristics of
the 8 patients are listed in Table 1.
Intraoperative Outcome
The transcatheter valve was successfully implanted
within the failed surgically implanted valve in all patients.
All transcatheter valves were well seated in the surgical
valves (Figure 2). One patient died on postoperative day
1. This patient had an Edwards SAPIEN 23-mm valve im-
planted inside a degenerated 21-mm Sorin Mitroflow peri-
cardial aortic valve. Immediately after implantation it
became apparent that a calcified leaflet of the failed bio-
prosthesis was obstructing the left main ostium (Figure 4).
The patient died despite emergent conversion to open-
heart AVR.18
No other intraoperative complications, particularly no
valve malpositioning, valve embolization, cardiac arrest,
major arrhythmia, or apical bleeding were observed. The
procedural characteristics are listed in Table 2.
Clinical Outcomes
Of the 7 survivors, 6 patients had excellent postoperative
recovery and had no early complications. They were all dis-
charged home. One patient had an uneventful operation and
good early postoperative recovery, but he developed a perfo-
ration of a large sigmoid diverticulum on postoperative day
4. This patient underwent bowel surgery and was dis-
charged on postoperative day 30. The mean hospital stay
was 9.0 9.1 days (median, 6.5 days). No other early post-
operative complications such as valve embolization/migra-
tion, postoperative bleeding, heart block or new pacemakerdiovascular Surgery c Volume 145, Number 6 1555
FIGURE 1. Balloon-expandable transcatheter bioprostheses and in vitro tests of valve-in-valve implantation.
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Dimplantation, pneumonia/sepsis, thromboembolic event/
stroke, or wound infection occurred (Table 2).
None of the remaining 7 patients had died at the last
follow-up of 18 to 55 months. No valve-related complica-
tions, such as stroke or transient ischemic attack,
myocardial infarction, major arrhythmia, endocarditis,
thromboembolic events, or valve structural deterioration/
dysfunction, occurred during the follow-up period. Most
patients experienced improvement in their symptoms and
quality of life. In the 7 survivors, 6 patients had improve-
ment in their heart failure symptoms (NYHA class), and 1
remained in NYHA class II-III because of pre-existing sig-
nificant chronic obstructive pulmonary disease (Table 3).
The 2-year survival was 87.5%, and no late mortality
occurred during the follow-up period.Echocardiographic Follow-up
The predischarge transthoracic echocardiogram docu-
mented an increase in the estimated aortic valve area from
0.8  0.2 cm2 preoperatively to 1.1  0.5 cm2 and a reduc-
tion in the transaortic mean gradient from 39.1  11.0 mm
Hg preoperatively to 27.5  12.2 mm Hg postoperatively
(Figure 5). The prosthetic valve area and transvalvular pres-
sure gradient remained stable at 24 months of follow-up
(Figure 5). The residual transaortic valve pressure gradient
was relatively high (range, 23-48 mm Hg) when the trans-
catheter valve was implanted into 21- and 23-mm surgical
valves. In contrast, the mean pressure gradient was less1556 The Journal of Thoracic and Cardiovascular Surthan 15 mm Hg (range, 11-13 mm Hg) when implanting
into 25-mm surgical tissue valves (Table 2). The mean pres-
sure gradient in each patient at discharge and 1 year of
follow-up is listed in Table 2 and Table 4, respectively.
Follow-up echocardiography demonstrated good valve
function in all patients up to 48 months. No prosthesis mi-
gration and no structural valve deterioration occurred.
Valvular or paravalvular aortic insufficiency was deter-
mined by echocardiography. Six survivors had no paravalv-
ular leak, and 1 patient had mild leakage at 12 months of
follow-up (Table 4). Improvements in mitral regurgitation
and tricuspid regurgitation were observed in 3 and 4
patients, respectively (Table 4).DISCUSSION
The risk of operativemortality and morbidity increases in
elderly patients who undergo reoperative AVR, although
AVR remains the reference standard therapy for failed pros-
thetic valves. At our center, 286 patients underwent isolated
repeat replacement of the aortic valve for prosthetic struc-
tural valve deterioration from 1975 to 1999, with an overall
operative mortality of 6.6%.1 The mortality in patients with
NYHA class IV was 16% and for those aged older than 70
years was 12.6%. Eitz and colleagues2 reported a 30-day
mortality of 16.4% in patients aged 80 years and older
undergoing reoperative AVR.
We performed the first transapical valve-in-valve AVI
into a failed aortic surgical bioprosthesis in humans ingery c June 2013
FIGURE 2. Transapical valve-in-valve implantation of a balloon-expandable transcatheter valve within a failed surgically implanted Edwards aortic
bioprosthesis with a metal frame at the base.
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D2007.19 Since 2008, many case reports19,20 and several case
series12-14 have been published of transcatheter valve-in-
valve implantation of either the CoreValve or Edwards
SAPIEN valve into failed aortic surgical bioprostheses.
These reports have demonstrated the feasibility and good
early 30-day outcomes. Transcatheter valve-in-valve im-
plantation with the Edwards valve is performed mainlyFIGURE 3. Transapical valve-in-valve implantation of a balloon-expandable
bioprosthesis without a metal frame at the base.
The Journal of Thoracic and Carusing the transapical approach. The present study has sum-
marized clinical and hemodynamic outcomes more than 2
years after transapical transcatheter valve-in-valve AVI.
Our results have further confirmed the feasibility and
safety of the valve-in-valve AVI and demonstrated good
early clinical outcomes. More importantly, the present
case series study has provided the longest clinical andtranscatheter valve within a failed surgically implanted Medtronic Mosaic
diovascular Surgery c Volume 145, Number 6 1557
TABLE 1. Baseline characteristics
Characteristic Patients (n) Mean ± SD or%
Age (y) 8 84.1  1.6
Hypertension 7 87.5%
Diabetes 1 12.5%
Coronary artery disease 7 87.5%
Previous myocardial infarction 5 62.5%
Severe lung disease 1 12.5%
Previous coronary artery bypass
grafting
6 75.0%
History of cerebral ischemic event 0 0%
Peripheral vascular disease 5 62.5%
History of gastrointestinal bleeding 2 25.0%
eGFR<60 mL/min 7 87.5%
Ejection fraction (%) 8 57.5  12.5
Pulmonary hypertension (mm Hg) 8 48.5  14.7
History of smoking 7 87.5%
Atrial fibrillation 3 37.5%
Permanent pacemaker 1 12.5%
euroSCORE
Additive 8 13.8  2.1
Logistic 8 42.1  15.7
STS score 8 14.4  9.6
SD, Standard deviation; euroSCORE, European System for Cardiac Operative Risk
Evaluation; eGFR, estimated glomerular filtration rate; STS, Society of Thoracic
Surgeons.
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Dechocardiographic follow-up of transcatheter valve-in-
valve AVI.
Survival and Clinical Outcomes During Follow-up
It has been well documented that the average survival of
patients with symptomatic aortic stenosis with congestive
heart failure symptoms is approximately 2 to 3 years. Pa-
tients with symptomatic native aortic stenosis declined for
surgery have a survival as low as 50% at 1 year and lessFIGURE 4. Left main obstruction after transapical valve-in-valve implantation
‘‘flat’’ sinus of Valsalva), a tightly fitted surgical valve, and low location of the
transcatheter heart value.
1558 The Journal of Thoracic and Cardiovascular Surthan 25% at 2 years.10,21 In our study, the 1-year survival
was 87.5%, with no additional mortality up to 4 years of
follow-up. This suggests that transapical valve-in-valve
AVI could improve survival in these extremely high-risk el-
derly patients who have symptomatic severe bioprosthetic
stenosis/regurgitation. Transapical valve-in-valve AVI was
also shown to provide symptomatic relief and quality
of life improvement. Most survivors had NYHA class I
heart failure symptoms after transapical valve-in-valve
AVI. Also, most of the survivors were satisfied with their
cardiac condition and were living independently at the
last follow-up.
Early procedure-related complications and late valve-
related complications, particularly stroke, were rare. No
early or late valve displacement or embolization, no
structural valve deterioration, and nonstructural valve
dysfunction had developed at a follow-up of 4 years. Echo-
cardiography demonstrated stable function of the balloon-
expandable transcatheter bioprosthetic valves at up to 4
years of follow-up. However, longer term durability of the
transcatheter tissue valve implanted into a surgical valve
remains to be determined.
Six patients (85.7%) had no paravalvular leakage during
follow-up, suggesting that the incidence of paravalvular
leaks might be lower after valve-in-valve implantation
into a surgical valve than after transcatheterAVI into a native
stenotic aortic valve.22 This was likely due to the more fa-
vorable sealing by the circular bioprosthetic valve frame/
stent and easy achievement of good positioningwhen ametal
frame was visible at the base of the bioprosthetic valves.
As observed in patients undergoing transcatheter AVI for
native aortic stenosis, patients with concomitant moderate
to severe mitral or tricuspid regurgitation appeared to
tolerate the transapical valve-in-valve AVI wellinto a failed SorinMitroflow aortic tissue valve. A, Small aortic root (a very
left main ostium. B, Left main obstruction. LM, Left main (artery); THV,
gery c June 2013
TABLE 2. Procedure characteristics and early outcomes
Pt no. Size and type of failed valve
Valve pathologic
findings
Preoperative
MG (mm Hg)
THV 9000TFX
(mm)
Intraoperative
complications
30-d
Complications
Echocardiography
at discharge
AI MG (mm Hg)
1 25-mm EC 2650 porcine AI 28 23 No No 0 11
2 23-mm EC 2650 porcine AIþAS 31 23 No No 0 24
3 23-mm EC 2650 porcine AS 62 23 No No 0 27
4 21-mm Ionescu-Shiley
pericardium
AS 40 23 No No Mild 23
5 25-mm EC 2650 porcine AS 38 26 No Perforated
diverticulitis
0 13
6 21-mm Medtronic porcine AIþAS 37 23 No Left pleural
effusion
0 48
7 21-mm Sorin Mitroflow
pericardium
AS 48 23 LM obstruction Died on POD 1 NA NA
8 23-mm Sorin Mitroflow
pericardium
AS 38 23 No No Mild 32
Pt no., Patient number; MG, mean gradient; THV, transcatheter heart valve; AI, aortic insufficiency; EC, Edwards-Carpentier; AS, aortic stenosis; LM, left main; POD, postop-
erative day; NA, not available.
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changed or decreased, and tricuspid regurgitation usually
improved after transapical valve-in-valve AVI (Table 4).
This suggests that a conservative approach to coexisting mi-
tral and tricuspid valve regurgitation could also be a reason-
able approach for selected high-risk patients with failed
aortic bioprostheses.
Surgical Techniques and Complications
Compared with transcatheter treatment of native aortic
valve stenosis, valvuloplasty could conceivably be elimi-
nated unless the bioprosthesis has critical stenosis, which
would reduce a potential risk of stroke or embolic events.
In this cohort of patients, the incidence of stroke after trans-
apical valve-in-valve AVI appeared to be less than that in
patients who underwent transapical AVI for native aortic
stenosis. Theoretically, coronary ostial obstruction after
valve-in-valve implantation is unlikely because a newly im-
planted transcatheter valve is deployed completely inside
the frame of an old bioprothesis. However, a small aortic
root (a very ‘‘flat’’ sinus of Valsalva), tightly fitted surgical
valve, low location of the left main ostium (short distanceTABLE 3. Clinical follow-up
Pt no.
Follow-up
duration (mo)
Survival
status
NYHA class
Preoperatively Postoperatively
1 55 Yes IV I
2 35 Yes IV I
3 33 Yes IV I
4 32 Yes IV I
5 25 Yes III (COPD) II-III (COPD)
6 24 Yes IV I
7 0 No IV NA
8 18 Yes IV I
Pt no., Patient number; NYHA, New York Heart Association;COPD, chronic obstruc-
tive pulmonary disease; NA, not available.
The Journal of Thoracic and Carfrom the aortic annulus), or globular calcification in a bio-
prosthetic cusp near the left main ostium are the potential
risk factors for left main obstruction (Figure 4). The valve
design with bioprosthetic cusps mounting outside the struts,
such as the Sorin Mitroflow aortic valve, might increase
a risk of left main obstruction, which was observed in 1
of our patients. However, this complication was not ob-
served in other patients with Sorin Mitroflow aortic tissue
valves who underwent transcatheter valve-in-valve AVI in
our case series and others.13 We believe the location of
the left main artery and the shape of the sinus of Valsalva
are probably more important than the valve design itself.
To avoid this significant complication, careful preoperative
assessment of the aortic root is still important in patients un-
dergoing the aortic valve-in-valve procedure.Positioning of Transcatheter Valves
The anchoring site of bioprosthesis for the transcatheter
valve is its sewing cuff, rather than its struts. Angiographic
imaging should be in a plane perpendicular to the prosthesis
to minimize foreshortening. It is critical that balloon-
expandable transcatheter valves are positioned as coaxial
as possible within a failed surgical prosthesis at deploy-
ment. In our experience, placing 25% to 30% of the
SAPIEN valve upstream of the inflow aspect (ventricular
side) of the bioprosthesis ensures that the fabric cuff of
the transcatheter valve is positioned optimally in relation
to the sewing ring of a surgical valve and provides both
a very secure intravalvular fixation and minimizes paravalv-
ular regurgitation (Figure 6). Rapid ventricular pacing
might be required to determine optimal positioning if
significant motion of a bioprosthesis occurs during the car-
diac cycles. Aortography is not particularly helpful for po-
sitioning. Echocardiography is the primary imaging
modality used to guide positioning if a surgical valve hasdiovascular Surgery c Volume 145, Number 6 1559
FIGURE 5. Echocardiographic follow-up on the aortic valve area and
mean pressure gradient of Edwards SAPIEN valves implanted into failed
surgical bioprostheses.
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Mosaic tissue valve (Figure 5).Sizing Considerations
The marketed size of bioprosthetic heart valves is typi-
cally described according to the external or metal frame
diameter. However, the internal diameter of a surgical valve
is more relevant for transcatheter valve selection. The inter-
nal diameter varies significantly by manufacturer and
model, despite the same marketed size, and the internal
diameter can still be misleading because no standardized re-
porting system is available. Moreover, the valve pathologic
findings can also influence the selection of a transcatheter
valve. The internal diameter of a failed bioprosthesis is usu-
ally not reduced if a bioprosthesis has severe regurgitation
without significant calcification of its cusps; however, it
might be smaller than its reported internal diameter if
significant calcification and/or pannus is present. TEE
(both 2-dimensional and 3-dimensional) and computed to-
mography might be helpful in the measurement of the inter-
nal diameter of a bioprosthesis.TABLE 4. Echocardiographic follow-up at 1 year
Pt
no.
MG (mm Hg) LVEF (%) A
Preoperative Postoperative Preoperative Postoperative Preoperative
1 28 15 65 65 Severe
2 31 18 35 45 Severe
3 62 27 45 45 Trivial
4 40 20 65 65 Mild
5 38 11 60 65 No
6 37 45 75 75 Severe
8 38 35 55 60 Mild
Pt no., Patient number; MG, mean gradient; LVEF, left ventricular ejection fraction; AI, a
1560 The Journal of Thoracic and Cardiovascular SurOptimal transcatheter valve function requires full expan-
sion to its nominal dimension. Ideally, the transcatheter
valve would be only slightly larger than, or equivalent to,
the internal diameter of the nonexpandable sewing cuff of
a surgical bioprosthesis. If a transcatheter valve is too
underexpanded, it can be expected to function suboptimally,
with a high residual transvalvular pressure gradient and in-
appropriate leaflet coaptation, with likely reduced durabil-
ity. The acceptable boundaries of underexpansion have
not been defined. In our experience, patients with severe
regurgitation can benefit from valve-in-valve implantation,
despite underexpansion, with a significant residual pressure
gradient. In contrast, a significantly underexpanded trans-
catheter valve might provide less clinical benefit to a patient
with a stenotic bioprosthesis. For example, a 23-mm
Edwards SAPIEN valve appears to result in acceptable he-
modynamic performance when implanted within a 23-mm
bioprosthetic surgical valve with an internal diameter of
approximately 19 to 20 mm. Implantation of this transcath-
eter valve within a 21-mm surgical valve is reasonable in
patients, particularly those with severe bioprosthetic regur-
gitation, despite a high residual gradient. In the present case
series, valve-in-valve implantation into 21-mm surgical
valves provides significant clinical benefits, regardless of
the pathologic findings (aortic stenosis or aortic insuffi-
ciency) of the surgical valve. Although we do not have
experience with 19-mm surgical valves, we believe implan-
tation within a 19-mm prosthesis is unlikely to be accept-
able in a patient, particularly a patient with stenosis. In
the present case series, the greatest mean pressure gradient
was 48 mm Hg in patient 6, who had a failed 21-mm Med-
tronic tissue valve. The reported internal stent diameter of
the 21-mm Medtronic mosaic tissue valve is 18.5 mm,
smaller than that of the 21-mm Edwards or St. Jude Medical
tissue valve.23 With a significant amount of the fabric cover,
the true internal diameter is even smaller. We believe the
high residual pressure gradient in this patient was likely
due to the small internal diameter. High residual mean pres-
sure gradients (range, 20-43 mm Hg) after implantation of
either the SAPIEN valve or CoreValve into 21- or 23-mm
surgical valves have also been reported by others.24,25 The
high gradient after a valve-in-valve procedure isI MR TR
Postoperative Preoperative Postoperative Preoperative Postoperative
No Mild Trivial Mild Trivial
No Moderate Mild Trivial Trivial
No Moderate Mild Moderate Mild
No Mild Mild None Trivial
No Mild Mild Trivial Trivial
No Severe Severe Moderate Mild
Mild Moderate Moderate Severe Moderate
ortic insufficiency; MR, mitral regurgitation; TR, tricuspid regurgitation.
gery c June 2013
FIGURE 6. Appropriate positioning of a transcatheter valve within a surgical valve as determined by fluoroscopy or echocardiography.
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cal valves, high residual pressure gradients might reflect the
use of valve-in-valve implantation as a palliative procedure.
Thus, the valve-in-valve procedure should be only offered
to elderly patients who are deemed to be too high risk to un-
dergo re-do AVR. The potential of a future valve-in-valve
option could be an additional reason for maximizing the
size of an initial surgical valve (25 mm), because our ini-
tial data have demonstrated that the residual transaortic
pressure gradient is minimal (<15 mm Hg) when
a 23-mm SAPIEN valve is implanted within 25-mm surgi-
cal valves. The availability of various sizes of transcatheter
valves and a standardized method of reporting the internal
diameter of bioprostheses is desirable to expand this option.
The feasibility of valve-in-valve AVI with either SAPIEN
valve or CoreValve into failed stentless bioprostheses has
also been reported; however, the experience is very
limited.26,27
Postoperative Anticoagulation
It is our current management to give aspirin and clopidog-
rel to patients who undergo AVI into a native aortic valve.
With up to 5 to 6 years of follow-up of these patients, stent
valve thrombosis and valve-related thrombotic events, in-
cluding stroke, have been very rare. In the present cohort of
patients who underwent valve-in-valve AVI into failed surgi-
cal tissue valves, 5 patients were given aspirin indefinitely
plus clopidogrel for at least 3months, and 2 patients received
aspirin plus warfarin for chronic atrial fibrillation. No stroke
or embolic events were reported during the follow-up period,
which might suggest that aspirin and clopidogrel are suffi-
cient to prevent thrombosis. However, this needs to be eval-
uated clinically in a relatively large sample size.The Journal of Thoracic and CarCONCLUSIONS
Transapical valve-in-valve AVI of balloon-expandable
valves into failed aortic surgical bioprostheses is safe with
acceptable early mortality and morbidity. Transapical
valve-in-valve AVI provides good clinical outcomes and
stable valve function longer than 2 years of follow-up.
The best hemodynamic and clinical outcomes can be
achieved in patients with a surgical valve size of 25 mm
or greater. Transapical valve-in-valve AVI might become
a viable approach for selected high-risk patients with failed
surgical bioprostheses. However, longer term follow-up is
required before this method can be more broadly applied.References
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